Novavax Vaccine Will Probably Work on New Covid Strain: CEO

The transcript discusses the efficacy of NovaVax's COVID vaccine against new strains, updates on phase trials, and comparisons with mRNA vaccines. It covers side effects, safety profiles, and the potential need to adapt vaccines for new strains. The company plans to scale up production and distribute globally, addressing public acceptance and herd immunity. NovaVax's future includes a robust pipeline of respiratory vaccines.

What is the main goal of the Phase 3 trials mentioned in the transcript?

• To determine the vaccine's side effects

• To test the vaccine's effectiveness against new strains

• To assess the vaccine's manufacturing process

• To compare the vaccine with other vaccines

How does the traditional vaccine from Nova VAX compare to mRNA vaccines in terms of efficacy?

• It has no efficacy

• It measures the same endpoints

• It is more effective

• It is less effective

What is the expected side effect profile of the vaccine based on early studies?

• Benign side effects

• Moderate side effects

• Severe side effects

• No side effects

What is the company's strategy if the vaccine needs to be tweaked for new strains?

• Immediate global distribution

• Conducting comparability studies

• No changes needed

• Halting production

Which company has Nova VAX partnered with for distribution in middle and lower income countries?

• Johnson & Johnson

• Pfizer

• Serum Institute in India

• Moderna

What percentage of vaccination is targeted to achieve herd immunity according to global health experts?

• 30-40%

• 50-60%

• 60-70%

• 80-90%

What is the focus of Nova VAX's future plans after the COVID-19 vaccine?

• Continuing to develop respiratory vaccines

• Shifting focus to cancer research

• Expanding into non-respiratory vaccines

• Developing new mRNA vaccines